Expression of the epigenetic H3K27me3 modifier genes KDM6A and EZH2 in patients with upper tract urothelial carcinoma

Wang,Yue; Zhang,Jin-Xia; Wang,Shu-Fang; Zhang,Yu; He,Hui-Ying

doi:10.3892/ol.2020.12212

Expression of the epigenetic H3K27me3 modifier genes KDM6A and EZH2 in patients with upper tract urothelial carcinoma

Authors:
- Yue Wang
- Jin-Xia Zhang
- Shu-Fang Wang
- Yu Zhang
- Hui-Ying He
View Affiliations

Affiliations: Department of Pathology, Peking University Shougang Hospital, Beijing 100144, P.R. China, Department of Pathology, School of Basic Medical Sciences, Peking University Third Hospital, Peking University Health Science Center, Beijing 100083, P.R. China
Published online on: October 10, 2020 https://doi.org/10.3892/ol.2020.12212
Article Number: 349

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The development of upper tract urothelial carcinoma (UTUC) has been associated with the ingestion of aristolochic acid (AA) in Chinese herbs. The tumors are more malignant and patients have a worse prognosis in China compared with that in Western countries. Recently, whole‑genome and exome sequencing of AA‑associated UTUCs found that the most frequently mutated gene was lysine demethylase 6A (KDM6A). However, its biological role and clinical significance have not yet been defined in patients with UTUC in China. A total of 108 surgically resected UTUC samples were obtained. Using immunohistochemistry, the protein expression level of KDM6A in the tumors was investigated together with the clinical and pathological characteristics of the patients, including survival times. In the present study, the expression level of KDM6A was significantly lower in UTUC specimens compared with that in samples from the normal urothelium. Lower KDM6A expression was also found to be significantly associated with a higher tumor grade and shorter cancer‑specific and disease‑free survival times (P=0.023 and P=0.033, respectively). In addition, using immunohistochemical analysis, no positive association was found between KDM6A expression and the expression of H3K27me3 or histone‑lysine N‑methyltransferase EZH2, a histone methyltransferase that generates H3K27me3. The results of the present study indicated that decreased KDM6A expression level was significantly associated with tumor grade and decreased survival time in UTUC, suggesting that KDM6A expression could be used as a prognostic marker in patients with UTUC in China.

View Figures

View References

1	Chen XP, Xiong GY, Li XS, Matin SF, Garcia M, Fang D, Wang TY, Yu W, Gong K, Song Y, et al: Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: Experience from a nationwide high-volume centre in China. BJU Int. 112:917–924. 2013.PubMed/NCBI
2	Singla N, Fang D, Su X, Bao Z, Cao Z, Jafri SM, Xiong G, Zhang L, Hutchinson R, Sagalowsky A, et al: A multi-institutional comparison of clinicopathologic characteristics and oncologic outcomes of upper tract urothelial carcinoma in China and the United States. J Urol. 197:1208–1213. 2016. View Article : Google Scholar : PubMed/NCBI
3	Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, Weng WH, Siew EY, Liu Y, Heng HL, et al: Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med. 5:197ra1012013. View Article : Google Scholar : PubMed/NCBI
4	Ler LD, Ghosh S, Chai X, Thike AA, Heng HL, Siew EY, Dey S, Koh LK, Lim JQ, Lim WK, et al: Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Sci Transl Med. 9:eaai83122017. View Article : Google Scholar : PubMed/NCBI
5	Van der Meulen J, Speleman F and Van Vlierberghe P: The H3K27me3 demethylase UTX in normal development and disease. Epigenetics. 9:658–668. 2014. View Article : Google Scholar : PubMed/NCBI
6	Nickerson ML, Dancik GM, Im KM, Edwards MG, Turan S, Brown J, Ruiz-Rodriguez C, Owens C, Costello JC, Guo G, et al: Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer. Clin Cancer Res. 20:4935–4948. 2014. View Article : Google Scholar : PubMed/NCBI
7	Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al: The mutational landscape of lethal castrate resistant prostate cancer. Nature. 487:239–243. 2012. View Article : Google Scholar : PubMed/NCBI
8	Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al: Mutational landscape and significance across 12 major cancer types. Nature. 502:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
9	Lan F, Bayliss PE, Rinn JL, Whetstine JR, Wang JK, Chen S, Iwase S, Alpatov R, Issaeva I, Canaani E, et al: A histone H3 lysine 27 demethylase regulates animal posterior development. Nature. 449:689–694. 2007. View Article : Google Scholar : PubMed/NCBI
10	Hong S, Cho YW, Yu LR, Yu H, Veenstra TD and Ge K: Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc Natl Acad Sci USA. 104:18439–18444. 2007. View Article : Google Scholar : PubMed/NCBI
11	Moch H, Humphrey PA, Ulbright TM, Cubilla AL and Reuter VE: WHO Classification of Tumours of the Urinary System and Male Genital Organ. International Agency for Research on Cancer (IARC); Lyon: pp. 1312016
12	Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW and Amin MB: Updates in the eighth edition of the Tumor-Node-Metastasis staging classification for urologic cancers. Eur Uro. l73:560–569. 2018. View Article : Google Scholar
13	Rubin MA, Dunn R, Strawderman M and Pienta KJ: Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol. 26:312–319. 2002. View Article : Google Scholar : PubMed/NCBI
14	Li YR, Yu KJ, Chang YH, Lin PH, Shao IH, Kan HC, Chu YC, Chuang CK, Pang ST and Liu CY: Predictors of intravesical recurrence after radical nephroureterectomy and prognosis in patients with upper tract urothelial carcinoma. Cancer Manag Res. 12:7439–7450. 2020. View Article : Google Scholar : PubMed/NCBI
15	Gossage L, Murtaza M, Slatter AF, Lichtenstein CP, Warren A, Haynes B, Marass F, Roberts I, Shanahan SJ, Claas A, et al: Clinical and pathological impact of VHL, PBRMI, BAPI, SETD2, KDM6A, and JARIDIc in clear cell renal cell carcinoma. Genes Chromosomes Cancer. 53:38–51. 2014. View Article : Google Scholar : PubMed/NCBI
16	Ntziachiristos P, Tsirigos A, Welstead GG, Trimarchi T, Bakogianni S, Xu L, Loizou E, Holmfeldt L, Strikoudis A, King B, et al: Contrasting roles for histone 3 lysine 27 demethylases in acute lymphoblastic leukemia. Nature. 514:513–517. 2014. View Article : Google Scholar : PubMed/NCBI
17	Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJC, Quinn MC, et al: Genomic analyses identify molecular subtypes if pancreatic cancer. Nature. 531:47–52. 2016. View Article : Google Scholar : PubMed/NCBI
18	Li SH, Lu HI, Huang WT, Tien WY, Lan YC, Lin WC, Tsai HT and Chen CH: The prognostic significance of histone demethylase UTX in esophageal squamous cell carcinoma. Int J Mol Sci. 19:2972018. View Article : Google Scholar
19	Paolicchi E, Crea F, Farrar WL, Green JE and Danesi R: Histone lysine demethylases in breast cancer. Crit Rev Oncol Hematol. 86:97–103. 2013. View Article : Google Scholar : PubMed/NCBI
20	Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 486:346–352. 2012. View Article : Google Scholar : PubMed/NCBI
21	Wang J, Liu L, Xi W, Long Q, Wang Y, Bai Q, Xia Y, Xu J and Guo J: Prognostic value of UTX expression in patients with clear cell renal cell carcinoma. Urol Oncol. 34:338.e19–27. 2016. View Article : Google Scholar
22	Kaneko S and Li X: X chromosome protects against bladder cancer in females via a KDM6A-dependent epigenetic mechanism. Sci Adv. 4:eaar55982018. View Article : Google Scholar : PubMed/NCBI
23	Martinez-Garcia E and Licht JD: Deregulation of H3K27 methylation in cancer. Nat Genet. 42:100–101. 2010. View Article : Google Scholar : PubMed/NCBI
24	Wu Q, Tian Y, Zhang J, Tong X, Huang H, Li S, Zhao H, Tang Y, Yuan C, Wang K, et al: In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis. Proc Natl Acad Sci USA. 115:E3978–E3986. 2018. View Article : Google Scholar : PubMed/NCBI
25	Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, et al: Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 118:3932–3941. 2011. View Article : Google Scholar : PubMed/NCBI
26	Kim KH and Roberts CW: Targeting EZH2 in cancer. Nat Med. 22:128–134. 2016. View Article : Google Scholar : PubMed/NCBI